Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
180 participants
OBSERVATIONAL
2025-07-01
2026-08-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is a multicentre, prospective cohort and audit study conducted in Türkiye. The study aims to evaluate the incidence of Lynch syndrome among patients who undergo surgery for colorectal cancer in participating general surgery departments.
Over a 12-month period, patients undergoing surgery for histologically confirmed colorectal cancer at multiple tertiary hospitals across Türkiye will be enrolled. Postoperative pathological assessments will include immunohistochemical (IHC) analysis for mismatch repair (MMR) protein expression (MLH1, PMS2, MSH2, and MSH6).
In cases showing loss of MLH1 and PMS2 expression, BRAF mutation testing will be performed. If BRAF mutation is detected, MLH1 promoter methylation analysis will follow. A positive result in both tests will suggest a sporadic etiology, whereas the absence of both findings will lead to referral for germline genetic testing using next-generation sequencing (NGS) to investigate Lynch syndrome.
For patients with isolated MSH2 and/or MSH6 loss, direct referral to genetic testing will be carried out without BRAF or methylation testing.
Patients with intact MMR expression will be recorded as the MMR-proficient control group. Comparative analysis will be conducted between dMMR and MMR-proficient patients, including demographic characteristics (age, sex, family history of cancer), tumor staging, anatomical location, and presence of metastases.
The primary outcome is to determine the incidence of Lynch syndrome among surgically treated colorectal cancer patients in Türkiye and to identify clinical and pathological correlations.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Malignancy on Morbidity and Mortality in Left-sided Emergency Colorectal Resections
NCT06958900
Advanced Geriatric Evaluation and Quality of Life in Colorectal Cancer Surgery
NCT04443816
Intracorporeal Versus Extracorporeal Anastomotic After Laparoscopic Right Colectomy
NCT05493033
Low Powered Colorectal Anastomosis After Rectal Excision (OASIS)
NCT07146334
The Impact of Colorectal Cancer Surgery on Localization of Ureters; Prospective Clinical Trail
NCT03007667
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is a multicentre, prospective cohort and audit study conducted in Türkiye. The study aims to evaluate the incidence of Lynch syndrome among patients who undergo surgery for colorectal cancer in participating general surgery departments.
Over a 12-month period, patients undergoing surgery for histologically confirmed colorectal cancer at multiple tertiary hospitals across Türkiye will be enrolled. Postoperative pathological assessments will include immunohistochemical (IHC) analysis for mismatch repair (MMR) protein expression (MLH1, PMS2, MSH2, and MSH6).
In cases showing loss of MLH1 and PMS2 expression, BRAF mutation testing will be performed. If BRAF mutation is detected, MLH1 promoter methylation analysis will follow. A positive result in both tests will suggest a sporadic etiology, whereas the absence of both findings will lead to referral for germline genetic testing using next-generation sequencing (NGS) to investigate Lynch syndrome.
For patients with isolated MSH2 and/or MSH6 loss, direct referral to genetic testing will be carried out without BRAF or methylation testing.
Patients with intact MMR expression will be recorded as the MMR-proficient control group. Comparative analysis will be conducted between dMMR and MMR-proficient patients, including demographic characteristics (age, sex, family history of cancer), tumor staging, anatomical location, and presence of metastases.
The primary outcome is to determine the incidence of Lynch syndrome among surgically treated colorectal cancer patients in Türkiye and to identify clinical and pathological correlations.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
dmmr
dmmr
diagnostic test
Group 1: MMR-Proficient Group Label: MMR-Proficient
Description: Patients with normal expression of MMR proteins on IHC analysis. No indication for further genetic testing.
Type: Observational Group
Group 2: dMMR Group Label: dMMR
Description: Patients with loss of MMR protein expression (MLH1, PMS2, MSH2, or MSH6) on IHC. These patients will undergo further molecular or genetic analysis to evaluate for Lynch syndrome.
Type: Observational Group
mmr expression normal
mmr expression normal
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
diagnostic test
Group 1: MMR-Proficient Group Label: MMR-Proficient
Description: Patients with normal expression of MMR proteins on IHC analysis. No indication for further genetic testing.
Type: Observational Group
Group 2: dMMR Group Label: dMMR
Description: Patients with loss of MMR protein expression (MLH1, PMS2, MSH2, or MSH6) on IHC. These patients will undergo further molecular or genetic analysis to evaluate for Lynch syndrome.
Type: Observational Group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Histologically confirmed diagnosis of colorectal adenocarcinoma
Undergoing surgical resection at one of the participating general surgery departments
Availability of formalin-fixed, paraffin-embedded (FFPE) tumor tissue for MMR analysis
Consent to participate in the study and undergo genetic testing if indicated
Exclusion Criteria
Diagnosis other than colorectal adenocarcinoma
Incomplete or unavailable postoperative pathology results
Inadequate tissue samples for IHC analysis
Patients who decline participation in the study at any point
Patients who do not attend or refuse referral to genetic counseling after pathology results
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Izmir Ataturk Training and Research Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
SAADET KOCA
md ftbs phd-c
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Hilal
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.